Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0ARIWN
ADC Name
CMD-193
Synonyms
CMD-193
   Click to Show/Hide
Organization
Wyeth (Top20 MNC) (Originator)
Drug Status
Phase 1 (discontinued)
Drug-to-Antibody Ratio
2~3
Structure
Antibody Name
G193
  Antibody Info 
Antigen Name
Lewis Y
  Antigen Info 
Payload Name
N-acetyl-gamma-calicheamicin
  Payload Info 
Therapeutic Target
Human deoxyribonucleic acid (hDNA)
  Target Info 
Linker Name
AcButDMH
  Linker Info 
Conjugate Type
Random Lysines
Combination Type
ozogamicin
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
Indication Phase 1 Phase 1/2 Phase 2 Phase 2/3 Phase 3 New Drug Application Approved
Unspecific solid tumor
3 Trials
Trial ID
NCT00161642
NCT00293215
NCT00257881
General Information of The ADMET Data Related to This ADC(2027 Update)
Absorption
Click To Hide/Show 27 Absorption Data Related to This Level
Standard Type Value Units Description Reference
Area Under the Concentration-Time Curve (AUC) 29.93 ug*h/mL
111In-CMD-193 serum pharmacokinetic analysis results, All (n=9).
 [1]
Area Under the Concentration-Time Curve (AUC) 16.37 ug*h/mL
111In-CMD-193 serum pharmacokinetic analysis results, 1 mg/m2 (n=6).
 [1]
Area Under the Concentration-Time Curve (AUC) 56.45 ug*h/mL
111In-CMD-193 serum pharmacokinetic analysis results, 2.6 mg/m2 (n=3).
 [1]
Area Under the Concentration-Time Curve (AUC) 80.2 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.094 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 258 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Female, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 271 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 905 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.94 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 74.3 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.094 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 264 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.336 mg/kg, Female, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 232 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.336 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 184 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.94 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 82 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.094 mg/kg, Male, AUCINF.
 [2]
Area Under the Concentration-Time Curve (AUC) 268 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Female, AUCINF.
 [2]
Area Under the Concentration-Time Curve (AUC) 283 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Male, AUCINF.
 [2]
Area Under the Concentration-Time Curve (AUC) 915 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.94 mg/kg, Male, AUCINF.
 [2]
Area Under the Concentration-Time Curve (AUC) 121 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.094 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 364 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Female, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 278 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 890 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.94 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 110 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.094 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 335 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.336 mg/kg, Female, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 269 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.336 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 274 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.94 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 121 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.094 mg/kg, Male, AUCINF.
 [2]
Area Under the Concentration-Time Curve (AUC) 383 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Female, AUCINF.
 [2]
Area Under the Concentration-Time Curve (AUC) 405 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Male, AUCINF.
 [2]
Area Under the Concentration-Time Curve (AUC) 930 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.94 mg/kg, Male, AUCINF.
 [2]
Distribution
Click To Hide/Show 44 Distribution Data Related to This Level
Standard Type Value Units Description Reference
Volume of Distribution (Vd) 4071.22 mL
111In-CMD-193 serum pharmacokinetic analysis results, All (n=9).
 [1]
Area Under the Concentration-Time Curve (AUC) 29.93 ug*h/mL
111In-CMD-193 serum pharmacokinetic analysis results, All (n=9).
 [1]
Volume of Distribution (Vd) 4366.18 mL
111In-CMD-193 serum pharmacokinetic analysis results, 1 mg/m2 (n=6).
 [1]
Area Under the Concentration-Time Curve (AUC) 16.37 ug*h/mL
111In-CMD-193 serum pharmacokinetic analysis results, 1 mg/m2 (n=6).
 [1]
Volume of Distribution (Vd) 3481.31 mL
111In-CMD-193 serum pharmacokinetic analysis results, 2.6 mg/m2 (n=3).
 [1]
Area Under the Concentration-Time Curve (AUC) 56.45 ug*h/mL
111In-CMD-193 serum pharmacokinetic analysis results, 2.6 mg/m2 (n=3).
 [1]
Area Under the Concentration-Time Curve (AUC) 80.2 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.094 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 258 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Female, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 271 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 905 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.94 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 74.3 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.094 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 264 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.336 mg/kg, Female, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 232 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.336 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 184 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.94 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 82 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.094 mg/kg, Male, AUCINF.
 [2]
Area Under the Concentration-Time Curve (AUC) 268 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Female, AUCINF.
 [2]
Area Under the Concentration-Time Curve (AUC) 283 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Male, AUCINF.
 [2]
Area Under the Concentration-Time Curve (AUC) 915 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.94 mg/kg, Male, AUCINF.
 [2]
Volume of Distribution (Vd) 84.1 mL/kg
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.094 mg/kg, Male.
 [2]
Volume of Distribution (Vd) 102 mL/kg
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Female.
 [2]
Volume of Distribution (Vd) 109 mL/kg
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Male.
 [2]
Volume of Distribution (Vd) 73.1 mL/kg
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.94 mg/kg, Male.
 [2]
Volume of Distribution (Vd) 87.2 mL/kg
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.094 mg/kg, Male.
 [2]
Volume of Distribution (Vd) 92 mL/kg
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.336 mg/kg, Female.
 [2]
Volume of Distribution (Vd) 114 mL/kg
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.336 mg/kg, Male.
 [2]
Area Under the Concentration-Time Curve (AUC) 121 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.094 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 364 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Female, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 278 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 890 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.94 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 110 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.094 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 335 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.336 mg/kg, Female, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 269 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.336 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 274 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.94 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 121 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.094 mg/kg, Male, AUCINF.
 [2]
Area Under the Concentration-Time Curve (AUC) 383 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Female, AUCINF.
 [2]
Area Under the Concentration-Time Curve (AUC) 405 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Male, AUCINF.
 [2]
Area Under the Concentration-Time Curve (AUC) 930 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.94 mg/kg, Male, AUCINF.
 [2]
Volume of Distribution (Vd) 66.8 mL/kg
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.094 mg/kg, Male.
 [2]
Volume of Distribution (Vd) 93.6 mL/kg
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Female.
 [2]
Volume of Distribution (Vd) 95.5 mL/kg
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Male.
 [2]
Volume of Distribution (Vd) 100 mL/kg
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.94 mg/kg, Male.
 [2]
Volume of Distribution (Vd) 66.6 mL/kg
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.094 mg/kg, Male.
 [2]
Volume of Distribution (Vd) 95.1 mL/kg
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.336 mg/kg, Female.
 [2]
Volume of Distribution (Vd) 156 mL/kg
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.336 mg/kg, Male.
 [2]
Metabolism
Click To Hide/Show 27 Metabolism Data Related to This Level
Standard Type Value Units Description Reference
Area Under the Concentration-Time Curve (AUC) 29.93 ug*h/mL
111In-CMD-193 serum pharmacokinetic analysis results, All (n=9).
 [1]
Area Under the Concentration-Time Curve (AUC) 16.37 ug*h/mL
111In-CMD-193 serum pharmacokinetic analysis results, 1 mg/m2 (n=6).
 [1]
Area Under the Concentration-Time Curve (AUC) 56.45 ug*h/mL
111In-CMD-193 serum pharmacokinetic analysis results, 2.6 mg/m2 (n=3).
 [1]
Area Under the Concentration-Time Curve (AUC) 80.2 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.094 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 258 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Female, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 271 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 905 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.94 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 74.3 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.094 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 264 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.336 mg/kg, Female, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 232 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.336 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 184 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.94 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 82 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.094 mg/kg, Male, AUCINF.
 [2]
Area Under the Concentration-Time Curve (AUC) 268 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Female, AUCINF.
 [2]
Area Under the Concentration-Time Curve (AUC) 283 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Male, AUCINF.
 [2]
Area Under the Concentration-Time Curve (AUC) 915 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.94 mg/kg, Male, AUCINF.
 [2]
Area Under the Concentration-Time Curve (AUC) 121 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.094 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 364 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Female, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 278 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 890 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.94 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 110 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.094 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 335 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.336 mg/kg, Female, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 269 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.336 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 274 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.94 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 121 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.094 mg/kg, Male, AUCINF.
 [2]
Area Under the Concentration-Time Curve (AUC) 383 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Female, AUCINF.
 [2]
Area Under the Concentration-Time Curve (AUC) 405 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Male, AUCINF.
 [2]
Area Under the Concentration-Time Curve (AUC) 930 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.94 mg/kg, Male, AUCINF.
 [2]
Excretion
Click To Hide/Show 66 Excretion Data Related to This Level
Standard Type Value Units Description Reference
Elimination Half-Life (t1/2) 4.76 h
Halflife-alpha, 111In-CMD-193 serum pharmacokinetic analysis results, All (n=9).
 [1]
Elimination Half-Life (t1/2) 102.88 h
Halflife-beta, 111In-CMD-193 serum pharmacokinetic analysis results, All (n=9).
 [1]
Clearance (CL) 113.22 mL/h
111In-CMD-193 serum pharmacokinetic analysis results, All (n=9).
 [1]
Area Under the Concentration-Time Curve (AUC) 29.93 ug*h/mL
111In-CMD-193 serum pharmacokinetic analysis results, All (n=9).
 [1]
Elimination Half-Life (t1/2) 5.47 h
Halflife-alpha, 111In-CMD-193 serum pharmacokinetic analysis results, 1 mg/m2 (n=6).
 [1]
Elimination Half-Life (t1/2) 104.42 h
Halflife-beta, 111In-CMD-193 serum pharmacokinetic analysis results, 1 mg/m2 (n=6).
 [1]
Clearance (CL) 130.04 mL/h
111In-CMD-193 serum pharmacokinetic analysis results, 1 mg/m2 (n=6).
 [1]
Area Under the Concentration-Time Curve (AUC) 16.37 ug*h/mL
111In-CMD-193 serum pharmacokinetic analysis results, 1 mg/m2 (n=6).
 [1]
Elimination Half-Life (t1/2) 3.32 h
Halflife-alpha, 111In-CMD-193 serum pharmacokinetic analysis results, 2.6 mg/m2 (n=3).
 [1]
Elimination Half-Life (t1/2) 99.79 h
Halflife-beta, 111In-CMD-193 serum pharmacokinetic analysis results, 2.6 mg/m2 (n=3).
 [1]
Clearance (CL) 79.56 mL/h
111In-CMD-193 serum pharmacokinetic analysis results, 2.6 mg/m2 (n=3).
 [1]
Area Under the Concentration-Time Curve (AUC) 56.45 ug*h/mL
111In-CMD-193 serum pharmacokinetic analysis results, 2.6 mg/m2 (n=3).
 [1]
Area Under the Concentration-Time Curve (AUC) 80.2 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.094 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 258 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Female, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 271 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 905 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.94 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 74.3 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.094 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 264 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.336 mg/kg, Female, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 232 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.336 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 184 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.94 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 82 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.094 mg/kg, Male, AUCINF.
 [2]
Area Under the Concentration-Time Curve (AUC) 268 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Female, AUCINF.
 [2]
Area Under the Concentration-Time Curve (AUC) 283 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Male, AUCINF.
 [2]
Area Under the Concentration-Time Curve (AUC) 915 ug*h/mL
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.94 mg/kg, Male, AUCINF.
 [2]
Clearance (CL) 1.15 mL/h/kg
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.094 mg/kg, Male.
 [2]
Clearance (CL) 1.26 mL/h/kg
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Female.
 [2]
Clearance (CL) 1.19 mL/h/kg
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Male.
 [2]
Clearance (CL) 1.03 mL/h/kg
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.94 mg/kg, Male.
 [2]
Clearance (CL) 1.26 mL/h/kg
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.094 mg/kg, Male.
 [2]
Clearance (CL) 1.27 mL/h/kg
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.336 mg/kg, Female.
 [2]
Clearance (CL) 1.45 mL/h/kg
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.336 mg/kg, Male.
 [2]
Clearance (CL) 5.11 mL/h/kg
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.94 mg/kg, Male.
 [2]
Elimination Half-Life (t1/2) 66 h
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.094 mg/kg, Male.
 [2]
Elimination Half-Life (t1/2) 78 h
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Female.
 [2]
Elimination Half-Life (t1/2) 79 h
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Male.
 [2]
Elimination Half-Life (t1/2) 53 h
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.94 mg/kg, Male.
 [2]
Elimination Half-Life (t1/2) 49 h
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.094 mg/kg, Male.
 [2]
Elimination Half-Life (t1/2) 61 h
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.336 mg/kg, Female.
 [2]
Elimination Half-Life (t1/2) 74 h
Mean CMD-193 PK parameters in rat following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.336 mg/kg, Male.
 [2]
Area Under the Concentration-Time Curve (AUC) 121 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.094 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 364 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Female, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 278 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 890 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.94 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 110 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.094 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 335 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.336 mg/kg, Female, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 269 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.336 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 274 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.94 mg/kg, Male, AUC0-336.
 [2]
Area Under the Concentration-Time Curve (AUC) 121 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.094 mg/kg, Male, AUCINF.
 [2]
Area Under the Concentration-Time Curve (AUC) 383 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Female, AUCINF.
 [2]
Area Under the Concentration-Time Curve (AUC) 405 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Male, AUCINF.
 [2]
Area Under the Concentration-Time Curve (AUC) 930 ug*h/mL
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.94 mg/kg, Male, AUCINF.
 [2]
Clearance (CL) 0.777 mL/h/kg
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.094 mg/kg, Male.
 [2]
Clearance (CL) 0.877 mL/h/kg
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Female.
 [2]
Clearance (CL) 0.815 mL/h/kg
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Male.
 [2]
Clearance (CL) 1.01 mL/h/kg
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.94 mg/kg, Male.
 [2]
Clearance (CL) 0.854 mL/h/kg
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.094 mg/kg, Male.
 [2]
Clearance (CL) 1 mL/h/kg
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.336 mg/kg, Female.
 [2]
Clearance (CL) 1.25 mL/h/kg
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.336 mg/kg, Male.
 [2]
Clearance (CL) 3.44 mL/h/kg
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.94 mg/kg, Male.
 [2]
Elimination Half-Life (t1/2) 60 h
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.094 mg/kg, Male.
 [2]
Elimination Half-Life (t1/2) 79 h
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Female.
 [2]
Elimination Half-Life (t1/2) 89 h
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.336 mg/kg, Male.
 [2]
Elimination Half-Life (t1/2) 79 h
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, cycle 1, 0.94 mg/kg, Male.
 [2]
Elimination Half-Life (t1/2) 47 h
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.094 mg/kg, Male.
 [2]
Elimination Half-Life (t1/2) 76 h
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.336 mg/kg, Female.
 [2]
Elimination Half-Life (t1/2) 97 h
Mean CMD-193 PK parameters in rat derived from total calicheamicin following intravenous dosing of CMD-193 for four cycles, Cycle 3, 0.336 mg/kg, Male.
 [2]
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 6 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT00161642
PHASE1
A Phase 1 Dose Escalation Study of CMD-193 in Subjects With Advanced Malignant Tumors.
Undisclosed  NCT00257881
PHASE1
Phase 1 Dose-Escalation Study of Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors
Undisclosed  NCT00293215
PHASE1
Phase I Biodistribution Study of 111-Indium-CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen
Complete Remission (CR)  NCT00293215
Phase 1
Biodistribution study of cmd-193 in patients with advanced tumours expressing the LEWIS-Y antigen.
Undisclosed  NCT00161642
Phase 1
Phase 1 dose-escalation study of intravenous CMD-193 in subjects with advanced malignant solid tumors.
Undisclosed  NCT00257881
Phase 1
Phase 1 biodistribution study of 111-indium-CMD-193 in patients with advanced tumours expressing the LEWIS-Y antigen.
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 99
%
NCI-N87 cells
Gastric tubular adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 6 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [3]
Patients Enrolled
Eligible patients must have histologically confirmed Lewis Y-positive (≥20%) solid tumors with ECOG 0-1, excluding those with recent cancer therapy (within 21-42 days), active CNS metastases, or severe prior protein allergies.
Administration Dosage
.
Related Clinical Trial
NCT Number NCT00161642  Clinical Status PHASE1
Clinical Description A Phase 1 Dose Escalation Study of CMD-193 in Subjects With Advanced Malignant Tumors.
Primary Endpoint
The study monitors safety through physical exams, hematology panels, and ECG monitoring for all participants.
Other Endpoint
Efficacy is assessed via radiographic tumor evaluations, while pharmacokinetic analyses are performed through blood sampling to measure drug exposure and response.
Experiment 2 Reporting the Activity Date of This ADC [4]
Patients Enrolled
Eligible patients must have advanced Lewis Y-positive solid tumors; exclusions involve recent anticancer therapy (within 28 days), pregnancy, or unstable medical conditions, ensuring patient safety and protocol compliance.
Administration Dosage
.
Related Clinical Trial
NCT Number NCT00257881  Clinical Status PHASE1
Clinical Description Phase 1 Dose-Escalation Study of Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors
Primary Endpoint
The primary safety assessments focus on dose-limiting toxicities and adverse events to evaluate treatment tolerability.
Other Endpoint
Secondary outcomes include pharmacokinetic measurements and tumor response evaluations to assess drug exposure and efficacy.
Experiment 3 Reporting the Activity Date of This ADC [5]
Patients Enrolled
Eligibility required Lewis Y-positive (&ge;20%) solid tumors with ECOG 0-1, measurable lesions &ge;2cm, and organ function thresholds. Exclusions included recent cancer therapy (<21-42 days), active CNS metastases, severe comorbidities, or prior protein allergies, ensuring protocol safety.
Administration Dosage
Subjects received 111-In-CMD-193 on Day 1 of Cycle 1. Subjects received CMD-193 at a dose of 1.0 mg/m^2 on Day 1 of subsequent 21-day cycles; Subjects received 111-In-CMD-193 on Day 1 of Cycle 1. Subjects received CMD-193 at a dose of 2.6 mg/m^2 on Day 1 of subsequent 21-day cycles.
Related Clinical Trial
NCT Number NCT00293215  Clinical Status PHASE1
Clinical Description Phase I Biodistribution Study of 111-Indium-CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen
Primary Endpoint
The study evaluated the biodistribution and pharmacokinetics of 111-In-CMD-193 using gamma camera imaging (Days 1-8) and serum sampling (Days 1-15). Key parameters included effective half-life, volume of central compartment, total clearance, and AUC extrapolated via a two-compartment model analyzed with WinNonLin 5.2.
Other Endpoint
Tumor response was assessed by RECIST (CT scans) and metabolic activity by EORTC criteria (18F-FDG-PET), tracking target lesion changes (CR, PR, SD, PD) and SUVmax variations at cycles 2, 4, and study completion.
Experiment 4 Reporting the Activity Date of This ADC [6]
Efficacy Data Complete Remission (CR)
0%
Patients Enrolled
Patients with advanced tumours expressing the Lewis-Y antigen.
Administration Dosage
111-In-CMD-193 iv then 1.00 mg/m^2, 2.60 mg/m^2 iv of CMD-193.
Related Clinical Trial
NCT Number NCT00293215  Clinical Status Phase 1
Clinical Description Biodistribution study of cmd-193 in patients with advanced tumours expressing the LEWIS-Y antigen.
Experiment 5 Reporting the Activity Date of This ADC [7]
Patients Enrolled
Patients with advanced malignant tumors.
Administration Dosage
CMD-193 iv.
Related Clinical Trial
NCT Number NCT00161642  Clinical Status Phase 1
Clinical Description Phase 1 dose-escalation study of intravenous CMD-193 in subjects with advanced malignant solid tumors.
Experiment 6 Reporting the Activity Date of This ADC [8]
Patients Enrolled
Patients with advanced malignant tumors.
Administration Dosage
CMD-193 iv.
Related Clinical Trial
NCT Number NCT00257881  Clinical Status Phase 1
Clinical Description Phase 1 biodistribution study of 111-indium-CMD-193 in patients with advanced tumours expressing the LEWIS-Y antigen.
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [9]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 99% Positive Lewis-Y expression (Lewis-Y +++/++)
Method Description
hu3S193-CalichDMH (4 ug) induces efficient tumor cell killing in cell line-derived models of PV-1 cells with CD28 expression.
In Vivo Model N193 CDX model
In Vitro Model Gastric tubular adenocarcinoma NCI-N87 cells CVCL_1603
References
Ref 1 Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers
Ref 2 PK of immunoconjugate anticancer agent CMD-193 in rats: ligand-binding assay approach to determine in vivo immunoconjugate stability
Ref 3 Study Evaluating CMD-193 in Advanced Malignant Solid Tumors
Ref 4 Study Evaluating Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors
Ref 5 Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen
Ref 6 Phase I Biodistribution Study of 111-Indium-CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen
Ref 7 A Phase 1 Dose Escalation Study of CMD-193 in Subjects With Advanced Malignant Tumors.
Ref 8 Phase 1 Dose-Escalation Study of Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors
Ref 9 Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts. Clin Cancer Res. 2004 Jul 1;10(13):4538-49. doi: 10.1158/1078-0432.CCR-04-0037.